Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R. Tibaldi C, et al. Among authors: orlandini c. Clin Cancer Res. 2008 Mar 15;14(6):1797-803. doi: 10.1158/1078-0432.CCR-07-1364. Clin Cancer Res. 2008. PMID: 18347182
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C, Ricci S, Russo F, Bernardini I, Galli L, Chioni A, Orlandini C, Grosso AM, Pegna AL, Fabbri A, Innocenti F, Ferrari K, Tognarini L, Conte PF, Falcone A; POLTO group. Tibaldi C, et al. Among authors: orlandini c. Lung Cancer. 2005 Apr;48(1):121-7. doi: 10.1016/j.lungcan.2004.10.008. Epub 2004 Dec 10. Lung Cancer. 2005. PMID: 15777979 Clinical Trial.
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Falcone A, et al. Among authors: orlandini c. J Clin Oncol. 2007 May 1;25(13):1670-6. doi: 10.1200/JCO.2006.09.0928. J Clin Oncol. 2007. PMID: 17470860 Clinical Trial.
A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P. Ricci S, et al. Among authors: orlandini c. Cancer. 2000 Oct 15;89(8):1714-9. doi: 10.1002/1097-0142(20001015)89:8<1714::aid-cncr10>3.0.co;2-7. Cancer. 2000. PMID: 11042565 Clinical Trial.
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, Ricci S, Del Tacca M, Danesi R. Di Paolo A, et al. Among authors: orlandini c. Clin Cancer Res. 2008 May 1;14(9):2749-55. doi: 10.1158/1078-0432.CCR-07-1529. Clin Cancer Res. 2008. PMID: 18451241 Free article.
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
Lencioni M, Falcone A, Allegrini G, Pfanner E, Masi G, Brunetti I, Di Marsico R, Fontana E, Orlandini C, Stampino CG, Bartolozzi C, Conte PF. Lencioni M, et al. Among authors: orlandini c. Oncology. 2000 Sep;59(3):204-9. doi: 10.1159/000012162. Oncology. 2000. PMID: 11053987 Clinical Trial.
75 results